Glenmark Life Sciences Limited
GLS.NS
National Stock Exchange of India1,086.00
INR
+1.65
- -
Glenmark Life Sciences Limited
GLS.NS
(National Stock Exchange of India)
Recent
price
1,086.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Glenmark Life Sciences Limited, now rebranded as Alivus Life Sciences, is an Indian pharmaceutical company specializing in the development, manufacture, and supply of high-quality active pharmaceutical ingredients (APIs) and intermediates. The company focuses on select high-value, non-commoditized APIs serving chronic therapeutic areas including cardiovascular, central nervous system, diabetes management, oncology, pain management, and anti-infectives. It also provides contract development and manufacturing organization (CDMO) services, offering custom synthesis, process development, and end-to-end support from research through clinical trials to commercial manufacturing, complying with stringent regulatory standards such as cGMP. Founded in 2019 and headquartered in Mumbai, Alivus Life Sciences operates manufacturing facilities that support regulatory approvals globally, serving over 700 customers, including leading generic pharmaceutical companies. The company’s core product portfolio includes APIs like Amiodarone and Telmisartan for cardiovascular diseases; Bupropion and Risperidone for CNS disorders; Teneligliptin and Linagliptin for diabetes; Tramadol and Etoricoxib for pain management; and Clindamycin and Lopinavir for anti-infective applications. It also manufactures pharmaceutical intermediates essential for API synthesis, maintaining high standards of quality and consistency. A major recent development is the acquisition of a 75% majority stake in Glenmark Life Sciences by Nirma Limited, a diversified Indian conglomerate, completed in March 2024. This strategic transaction marked a significant ownership and branding change, with the company rebranded as Alivus Life Sciences to reflect its evolving global vision and commitment to innovation in the API and CDMO sectors. Operationally, the company has expanded capacity with new manufacturing volumes added in Ankleshwar and Dahej and ongoing expansions in Solapur. The product development pipeline has grown with new APIs, including high-potency oncology APIs, targeting a large addressable market. Despite challenges such as temporary facility closures in FY25, Alivus Life Sciences projects strong revenue growth supported by a robust order book and improved gross margins exceeding 55%, reflecting favorable product mix and operational efficiencies. Alivus Life Sciences serves a global customer base with a presence primarily in India but with manufacturing and commercial reach extending internationally. It operates within the pharmaceutical manufacturing and contract development segments, providing essential ingredients and services that underpin drug production worldwide. This company is a subsidiary of Nirma Limited, which provides strategic and financial backing, bolstering Alivus Life Sciences’ position as an innovator and reliable supplier in the pharmaceutical API industry. The company’s headquarters is located in Mumbai, India, and it was originally established as part of the Glenmark Pharmaceuticals group before the recent divestiture and rebranding.